Half of the patients were in the IIB–IIIA clinical stage, while the majority of patients were characterized by Ki67 >55 (58%), the lack of lymph node metastasis (64%), and size of tumor ≤4 cm (60%). This evidence concerns the gene MKI67 and neoplasm.